Stock ALKS ALKERMES PLC
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Alkermes plc

Equities

ALKS

IE00B56GVS15

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
24.68 USD +0.98% Intraday chart for Alkermes plc +3.48% -11.03%
Apr. 09 Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday MT
Apr. 09 Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
PR
Alkermes to Report First Quarter Financial Results on May 1, 2024
PR
Alkermes Announces Positive Topline Results from Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients with Narcolepsy Type 2 and Idiopathic Hypersomnia
AQ
BlackBerry, Alkermes rise; Neogen, Tilray Brands fall, Tuesday, 4/9/2024
AQ
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
PR
Alkermes: Q4 Earnings Snapshot
AQ
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
PR
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
PR
Alkermes Announces Topline Results from Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI
AQ
Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR
Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk
PR
Alkermes to Participate in Two Upcoming Investor Conferences
PR
Alkermes Completes Separation of Oncology Business
PR
Alkermes to Participate in the Jefferies London Healthcare Conference
PR
Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement
PR
Alkermes : Q3 2023 Earnings Call Prepared Remarks
PU
Alkermes: Q3 Earnings Snapshot
AQ
Alkermes plc Reports Third Quarter 2023 Financial Results
PR
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
PR
Alkermes to Report Third Quarter Financial Results on October 25, 2023
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALKS Stock
  4. News Alkermes plc
  5. Press Releases